BGI announces that its Hemoglobinopathy Gene Detection Kit (Combinatorial Probe-Anchor Synthesis Sequencing Method) has just got CE-IVDD approval.

This kit can be utilized on high-throughput sequencing platforms for the genetic diagnosis of α-thalassemia, β-thalassemia, sickle cell disease, and other abnormal hemoglobinopathies. It can also be used for carrier screening of hemoglobinopathies in the general population.

Therefore, the CE-IVDD approval allows BGI to officially provide clinical references for the diagnosis or screening of thalassemia, sickle cell disease, and other abnormal hemoglobinopathies.